Related references
Note: Only part of the references are listed.Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Apostolia M. Tsimberidou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
Rami S. Komrokji et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Risk categories and refractory CLL in the era of chemoimmunotherapy
Thorsten Zenz et al.
BLOOD (2012)
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature
Stephane Lepretre et al.
LEUKEMIA & LYMPHOMA (2012)
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
Xavier C. Badoux et al.
BLOOD (2011)
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Xavier C. Badoux et al.
BLOOD (2011)
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia
S. H. Tonino et al.
ONCOGENE (2011)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger et al.
BLOOD (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia
S. H. Tonino et al.
LEUKEMIA (2010)
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:: a prospective randomized HOVON trial
Edo Vellenga et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
Alejandro Martin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
J. E. Castro et al.
LEUKEMIA (2008)
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Rekha Harting et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
Constantine S. Tam et al.
LEUKEMIA & LYMPHOMA (2007)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P. Dreger et al.
LEUKEMIA (2007)
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
Apostolia-Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High-risk fludarabine-pretreated B-Cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Ignazio Majolino et al.
MEDICAL ONCOLOGY (2006)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
P Moreton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
AM Tsimberidou et al.
CANCER (2003)
Results of first salvage therapy for patients refractory to a fluidarabine regimen in chronic lymphocytic leukemia
MJ Keating et al.
LEUKEMIA & LYMPHOMA (2002)
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
AM Tsimberidou et al.
LEUKEMIA & LYMPHOMA (2002)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
BS Dabaja et al.
LEUKEMIA & LYMPHOMA (2001)
Share Paper
